Repatha, manufactured by Amgen, is a PCSK9 inhibitor used to lower low-density lipoprotein cholesterol (LDL-C) [1]. It is prescribed to adults with high cholesterol who cannot reach their LDL-C goals with maximally tolerated statin therapy, or for individuals with certain inherited high cholesterol conditions, such as heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) [1][2]. Repatha works by reducing the amount of LDL cholesterol in the blood [1].
How does Repatha work to lower cholesterol?
Repatha functions by targeting and inhibiting the PCSK9 protein [1]. This protein normally binds to LDL receptors on liver cells and promotes their degradation, thereby reducing the liver's ability to remove LDL cholesterol from the bloodstream. By inhibiting PCSK9, Repatha allows more LDL receptors to remain on the liver cell surface, leading to increased clearance of LDL cholesterol from the blood [1][3].
What are the different formulations of Repatha?
Amgen offers Repatha in two forms: a SureClick autoinjector and a prefilled syringe [1]. Both are for subcutaneous injection [1].
What is the clinical data supporting Repatha's effectiveness?
Clinical trials have demonstrated Repatha's ability to significantly reduce LDL-C levels in patients with HeFH and HoFH, as well as in those with high cardiovascular risk on statin therapy [1]. Studies such as the Further Cardiovascular Outcomes Research with PCSK9 Inhibition and Included Variables (FOURIER) trial have shown that Repatha, when added to statin therapy, reduces the risk of major adverse cardiovascular events in patients with established cardiovascular disease [4].
When does Repatha's patent protection expire?
Information regarding specific patent expiry dates for Repatha can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed patent information, including expiry dates, for numerous drugs, which can be accessed to understand the patent landscape for Repatha [5].
Can generic or biosimilar versions of Repatha become available?
The availability of generic or biosimilar versions of Repatha depends on patent expiry and any associated regulatory exclusivities. Once patent protection lapses and all exclusivities are expired, other manufacturers may seek to market their own versions of the drug, which for biologic drugs like Repatha are termed biosimilars. The process for biosimilar approval in the United States is governed by the FDA [6].
What are the potential side effects of Repatha?
Common side effects of Repatha include nasopharyngitis (common cold), influenza, upper respiratory tract infection, and injection site reactions [1]. Serious allergic reactions have also been reported [1].
What is Repatha's role in managing cardiovascular risk?
For patients with high cholesterol and established cardiovascular disease or at high risk of cardiovascular events, Repatha is used as an adjunct to diet and maximally tolerated statin therapy. Its ability to substantially lower LDL-C levels contributes to reducing the risk of heart attack, stroke, and other cardiovascular events [1][4].
Who manufactures Repatha?
Repatha is developed and manufactured by Amgen [1].
How does Repatha compare to other cholesterol-lowering medications?
Unlike statins, which primarily inhibit cholesterol synthesis in the liver, Repatha targets the PCSK9 protein to enhance LDL receptor activity. This dual approach allows for greater LDL-C reduction in many patients, particularly those who do not achieve sufficient lowering with statins alone or are statin-intolerant [1][3].
What are the costs associated with Repatha?
The cost of Repatha can vary based on insurance coverage, pharmacy, and geographic location. Patients are often advised to check with their insurance provider or use manufacturer discount programs for potential cost savings [1].
Sources:
[1] https://www.repatha.com/
[2] https://www.amgen.com/
[3] https://www.drugpatentwatch.com/about/how-it-works
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1711128
[5] https://www.drugpatentwatch.com/
[6] https://www.fda.gov/drugs/biosimilars/biosimilar-medical-products